Treatment with more potent statins may increase the risk of new-onset diabetes, according to Muhammad M. Mamdani, PharmD, MPH, of St. Michael’s Hospital and the Institute for Clinical Evaluative Sciences in Toronto, Ontario, Canada, and colleagues.
In a retrospective study of individuals aged 66 years and older, the researchers found a 22% increased risk of incident diabetes associated with atorvastatin use, an 18% increased risk with rosuvastatin use, and a 10% increased risk with simvastatin use compared with pravastatin, which was the reference drug.
The absolute risk for incident diabetes was approximately 31 and 34 events per 1,000 person-years for atorvastastin and rosuvastatin, respectively, the researchers reported online ahead of print in BMJ. Simvastatin use was associated with a slightly lower risk (26 events per 1,000 person-years.
Researchers found no significantly increased diabetes risk among patients who received fluvastatin or lovastatin.